Teva, Sanofi Study Shows 58% UC Remission at 900 mg Over 44 Weeks
Teva and Sanofi’s RELIEVE UCCD study of duvakitug maintained durable efficacy over 58 weeks in 130 ulcerative colitis and Crohn’s patients. At week 44, 58% on 900 mg and 47% on 450 mg achieved ulcerative colitis remission, while 55% and 41% saw endoscopic response in Crohn’s.
1. Study Overview
The RELIEVE UCCD long-term extension trial evaluated duvakitug, a monoclonal antibody targeting TL1A, in 130 patients with ulcerative colitis or Crohn’s disease who had responded to induction therapy. Participants were re-randomized to receive 450 mg or 900 mg subcutaneous doses every four weeks for up to 58 weeks of exposure.
2. Efficacy Findings
At 44 weeks, clinical remission was achieved by 58% of ulcerative colitis patients on 900 mg and 47% on 450 mg, while endoscopic response rates in Crohn’s patients reached 55% and 41% at the respective doses. Both regimens were well tolerated and showed consistent benefits across additional efficacy endpoints.
3. Market Reaction
Teva shares trade 6.3% below their 20-day SMA and 10.5% below their 100-day SMA, with an RSI at neutral 50 and MACD below its signal line, indicating mixed momentum. Analysts at Goldman Sachs raised their price target to $45, Barclays to $38 and Scotiabank to $40, maintaining a Buy or Outperform consensus.